Epithelial SOX9 drives progression and metastases of gastric adenocarcinoma by promoting immunosuppressive tumour microenvironment.

Autor: Fan Y; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Li Y; Department of Surgical Oncology and General Surgery, First Hospital of China Medical University, Shenyang, PR China., Yao X; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Jin J; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Scott A; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Liu B; Department of Biology and Biochemistry, University of Houston, Houston, TX, USA., Wang S; Department of Biology and Biochemistry, University of Houston, Houston, TX, USA., Huo L; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Wang Y; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Wang R; Departments of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Pool Pizzi M; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Ma L; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Shao S; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Sewastjanow-Silva M; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Waters R; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Chatterjee D; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Liu B; Department of Epigenet & Mol Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Shanbhag N; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Peng G; Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Calin GA; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Mazur PK; Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Hanash SM; Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Ishizawa J; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Hirata Y; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Nagano O; Division of Gene Regulation, Institute for Advanced Medical Research, Keio University School of Medicine Graduate School of Medicine, Tokyo, Japan., Wang Z; Department of Surgical Oncology and General Surgery, First Hospital of China Medical University, Shenyang, PR China., Wang L; Departments of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Xian W; Department of Biology and Biochemistry, University of Houston, Houston, TX, USA., McKeon F; Department of Biology and Biochemistry, University of Houston, Houston, TX, USA., Ajani JA; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA ssong@mdanderson.org jajani@mdanderson.org jajani@mdanderson.org., Song S; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA ssong@mdanderson.org jajani@mdanderson.org jajani@mdanderson.org.

Publikováno v: Gut [Gut] 2023 Apr; Vol. 72 (4), pp. 624-637. Date of Electronic Publication: 2022 Aug 24.

GRK3 is a poor prognosticator and serves as a therapeutic target in advanced gastric adenocarcinoma.

Autor: Li Y; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX, 77030, USA.; Department of Surgical Oncology and General Surgery, First Hospital of China Medical University, Shenyang, 110001, People's Republic of China., Fan Y; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX, 77030, USA.; Department of Surgical Oncology and General Surgery, First Hospital of China Medical University, Shenyang, 110001, People's Republic of China., Xu J; Brown Foundation Institute of Molecular Medicine for the Prevention of Human Diseases, McGovern Medical School, The University of Texas Health Science Center, 1825 Pressler St., Houston, TX, 77030, USA.; Fujian Maternity and Child Health Hospital, Affiliated Hospital of Fujian Medical University, Fuzhou, 350001, People's Republic of China., Huo L; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX, 77030, USA., Scott AW; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX, 77030, USA., Jin J; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX, 77030, USA., Yang B; Brown Foundation Institute of Molecular Medicine for the Prevention of Human Diseases, McGovern Medical School, The University of Texas Health Science Center, 1825 Pressler St., Houston, TX, 77030, USA., Shao S; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX, 77030, USA., Ma L; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX, 77030, USA., Wang Y; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX, 77030, USA., Yao X; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX, 77030, USA., Pool Pizzi M; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX, 77030, USA., Sewastjanow Da Silva M; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX, 77030, USA., Zhang G; Brown Foundation Institute of Molecular Medicine for the Prevention of Human Diseases, McGovern Medical School, The University of Texas Health Science Center, 1825 Pressler St., Houston, TX, 77030, USA., Zhuo L; Brown Foundation Institute of Molecular Medicine for the Prevention of Human Diseases, McGovern Medical School, The University of Texas Health Science Center, 1825 Pressler St., Houston, TX, 77030, USA., Cho EJ; Division of Chemical Biology and Medicinal Chemistry, College of Pharmacy, The University of Texas at Austin, Austin, TX, 78712, USA., Dalby KN; Division of Chemical Biology and Medicinal Chemistry, College of Pharmacy, The University of Texas at Austin, Austin, TX, 78712, USA., Shanbhag ND; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX, 77030, USA., Wang Z; Department of Surgical Oncology and General Surgery, First Hospital of China Medical University, Shenyang, 110001, People's Republic of China. josieon826@sina.cn., Li W; Brown Foundation Institute of Molecular Medicine for the Prevention of Human Diseases, McGovern Medical School, The University of Texas Health Science Center, 1825 Pressler St., Houston, TX, 77030, USA. wenliang.li@uth.tmc.edu., Song S; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX, 77030, USA. ssong@mdanderson.org., Ajani JA; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX, 77030, USA. jajani@mdanderson.org.

Publikováno v: Journal of experimental & clinical cancer research : CR [J Exp Clin Cancer Res] 2022 Aug 23; Vol. 41 (1), pp. 257. Date of Electronic Publication: 2022 Aug 23.

BET inhibition revealed varying MYC dependency mechanisms independent of gene alterations in aggressive B-cell lymphomas.

Autor: Delrieu, Loris¹ (AUTHOR), Hamaidia, Sieme^1,2 (AUTHOR), Montaut, Emilie^1,2 (AUTHOR), Garcia-Sandoval, Andrea Cecilia¹ (AUTHOR), Teste, Camille¹ (AUTHOR), Betton-Fraisse, Patricia¹ (AUTHOR), Bonnefoix, Thierry^1,2 (AUTHOR), Carras, Sylvain^1,3,4 (AUTHOR), Gressin, Rémy^1,4 (AUTHOR), Lefebvre, Christine^1,3 (AUTHOR), Govin, Jérôme¹ (AUTHOR), Emadali, Anouk^1,2 (AUTHOR) anouk.emadali@univ-grenoble-alpes.fr

Publikováno v: Clinical Epigenetics. 12/19/2024, Vol. 16 Issue 1, p1-18. 18p.

Single-cell dissection of intratumoral heterogeneity and lineage diversity in metastatic gastric adenocarcinoma.

Autor: Wang R; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Dang M; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Harada K; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Department of Gastroenterological Surgery, Kumamoto University, Kumamoto, Japan., Han G; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Wang F; Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Pool Pizzi M; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Zhao M; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Tatlonghari G; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Zhang S; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Hao D; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Lu Y; Department of Nuclear Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Zhao S; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Badgwell BD; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Blum Murphy M; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Shanbhag N; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Estrella JS; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Roy-Chowdhuri S; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Abdelhakeem AAF; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Wang Y; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Peng G; Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Hanash S; Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Calin GA; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Song X; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Chu Y; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Zhang J; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Li M; Department of Biostatistics and Epidemiology, University of Pennsylvania School of Medicine, Philadelphia, PA, USA., Chen K; Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Lazar AJ; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Futreal A; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Song S; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Ajani JA; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. jajani@mdanderson.org., Wang L; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. LWang22@mdanderson.org.; UTHealth Graduate School of Biomedical Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. LWang22@mdanderson.org.

Publikováno v: Nature medicine [Nat Med] 2021 Jan; Vol. 27 (1), pp. 141-151. Date of Electronic Publication: 2021 Jan 04.

Extracellular vesicles miR‐31‐5p promotes pancreatic cancer chemoresistance via regulating LATS2‐Hippo pathway and promoting SPARC secretion from pancreatic stellate cells.

Autor: Qin, Cheng^1,2,3 (AUTHOR), Zhao, Bangbo^1,2,3 (AUTHOR), Wang, Yuanyang^1,2,3 (AUTHOR), Li, Zeru^1,2,3 (AUTHOR), Li, Tianyu^1,2,3 (AUTHOR), Zhao, Yutong^1,2,3 (AUTHOR), Wang, Weibin^1,2,3 (AUTHOR) wwb_xh@163.com, Zhao, Yupei^1,2,3 (AUTHOR) zhao8028@263.net

Publikováno v: Journal of Extracellular Vesicles. Aug2024, Vol. 13 Issue 8, p1-24. 24p.